Xin Li

Xin li graduated from Tianjin Medical University, Tianjin, China, and started postdoctoral fellow training in June, 2022. My present project focuses on T cell immune therapy, and previous project focuses on drug resistance in multiple myeloma.

Zhiwu Jiang

Zhiwu Jiang received his PhD in Guangzhou Institutes of Biomedicine and Health, China Academy of Science where he focused on the T cell immunotherapy against tumors. He joined Lu’s lab in March 2022, working on the immunotherapy project. His research mainly focuses on the development of novel immunotherapy to treat leukemia and solid tumors by using CAR-T, identifying new cancer-specific antigens, and developing novel strategies.

Muhammad Kalim

Muhammad Kalim received his PhD in Biochemistry and Molecular Biology at Zhejiang University China where he studied development of monoclonal antibodies (mAb) and antibody drug conjugates (ADC) for cancer immunotherapy. He joined Dr. Yong Lu’s lab focusing on novel scFv sequence development and target protein identification in cancer immunotherapy. In his free time, he enjoys outdoors activities and playing cricket.

Jing Fang

Ms. Jing Fang received her Master of Science degree from Texas Southern University majoring in Chemistry, where she started her research on cancer as a graduate research assistant. Her main research focus now is on cancer adoptive T cell immunotherapy.

Rui Jing

Rui Jing got her PhD at Second Military Medical University in July 2021, where she focused on the efficacy and mechanism of small compounds on chemotherapy-induced Leukopenia. She joined Lu’s Lab in June 2023 as a postdoctoral fellow. Now, her main research focus is developing new tumor-specific Th9 cell-paradigm to eradicate advanced human tumors.

Wei Guo

Wei Guo received his PhD degree in Shanghai Institute of Materia Medica, China Academy of Science where he focused cancer biology and cancer pharmacology. He joined Lu’s lab in March 2023 as a postdoctoral fellow, focusing on the development of CAR-T cell therapy for solid tumors and novel strategy to overcome the obstacles posed by TME-induced dysfunction of CAR-T cells

Pan Su

Pan Su received his PhD in Shanghai Institute of Biochemistry and Cell Biology, China Academy of Science where he focused on the regulation of autoimmune responses and autoimmune diseases, like Multiple sclerosis and Asthma. He joined the Yi lab in November 2016, working on the tumor biology project. His research mainly focuses on determining the mechanisms about the regulatory role of tumor microenvironment and tumor associated-macrophages (TAMs) during the development, progression, and drug resistance in multiple myeloma. He also focuses on the tumor immunotherapy and the regulation of anti-tumor effect of T cells in tumor microenvironment. Pan Su enjoys some outdoor activities, fishing, traveling and reading in his spare time.

Xiaoxuan Wang

Xiaoxuan Wang received her PhD in Tianjin Medical University in July 2022, where she studied of molecular biology/ biochemistry and oncology. She joined Lu’s lab in Sep 2022 as a postdoctoral fellow, focusing on bioinformatics and development of novel immunotherapy of cancers by using CAR-T.

Jingya Wang

Jingya Wang received her Ph.D. in 2017 in biochemistry and molecule biology from Nankai University, China. Her interest lies in understanding the T cell function in inflammation and cancer. She joined Lu’s lab in September 2023. Her research mainly focuses on mechanisms of resistance to CAR T cell therapy and identifying key molecule that enhances T cell-based immunotherapy

Ziyi Peng

Ziyi Peng graduated from Tianjin Medical University where she focused on developing new immunotherapies for Multiple Myeloma. She joined Lu’s lab in Sep 2023 as a postdoctoral fellow.